Sarepta Therapeutics (NASDAQ:SRPT) Issues Earnings Results, Beats Estimates By $0.42 EPS

Sarepta Therapeutics (NASDAQ:SRPT) issued its quarterly earnings results on Wednesday. The biotechnology company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.42, FiscalAI reports. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The business had revenue of $401.25 million for the quarter, compared to the consensus estimate of $366.39 million. During the same quarter in the previous year, the company posted $2.02 earnings per share. Sarepta Therapeutics’s revenue for the quarter was down 34.3% compared to the same quarter last year.

Here are the key takeaways from Sarepta Therapeutics’ conference call:

• 2026 net product revenue guidance was narrowed to $1.2 billion–$1.3 billion, with second-half revenue expected to be modestly below the first half and ELEVIDYS revenue likely lower in the third quarter. Management said improving enrollment forms may contribute more meaningfully to revenue in 2027.
• Sarepta reported Q2 GAAP operating income of $13 million and non-GAAP operating income of $86 million, while cash and investments increased by approximately $197 million to $945 million. The company also raised collaboration and other revenue guidance to $550 million–$600 million, primarily due to higher Roche contract-manufacturing revenue.
• ELEVIDYS enrollment-form activity improved sequentially as the expanded commercial organization became fully operational, with increased engagement from returning sites and interest from new referral sites. However, management cautioned that the typical approximately six-month enrollment-to-infusion timeline delays the revenue impact.
• The FDA accepted supplemental applications for AMONDYS 45 and VYONDYS 53 seeking conversion from accelerated to traditional approval, with a target action date of February 28, 2027. Sarepta said the applications are supported by the ESSENCE confirmatory study and substantial real-world evidence.
• Key pipeline catalysts include second-half 2026 interim MAD-study data for the SRP-1001 FSHD and SRP-1003 DM1 programs, early Huntington’s disease proof-of-biology data expected in early 2027, and full 12-week data from ELEVIDYS ENDEAVOR cohort 8 expected in the first quarter of 2027.

Sarepta Therapeutics Stock Up 5.3%

NASDAQ SRPT traded up $0.85 during trading on Thursday, hitting $16.78. 5,217,791 shares of the company traded hands, compared to its average volume of 3,106,438. The company has a market capitalization of $1.77 billion, a P/E ratio of -17.48, a PEG ratio of 0.18 and a beta of 0.23. The business has a fifty day simple moving average of $16.95 and a 200 day simple moving average of $18.55. Sarepta Therapeutics has a 12 month low of $14.68 and a 12 month high of $25.32. The company has a current ratio of 4.63, a quick ratio of 2.62 and a debt-to-equity ratio of 0.56.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Zacks Research cut shares of Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 7th. Weiss Ratings raised Sarepta Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, July 20th. Piper Sandler lowered their target price on Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a research note on Thursday, July 9th. Wolfe Research raised Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a research report on Thursday, July 9th. Finally, Wall Street Zen raised Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, July 4th. Nine research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and six have given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $24.72.

Key Headlines Impacting Sarepta Therapeutics

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Q2 results exceeded expectations. Sarepta reported adjusted earnings of $0.64 per share, versus the $0.22 consensus estimate, while revenue of $401.25 million topped forecasts of $366.39 million. The company also reported $13 million in GAAP operating income. Sarepta Second Quarter 2026 Financial Results
• Positive Sentiment: Expense guidance was tightened. Management narrowed its spending outlook, supporting expectations for better profitability and cash-flow management despite ongoing commercial challenges.
• Positive Sentiment: The pipeline provided additional support. Sarepta highlighted progress in its siRNA programs and other precision genetic medicines, while new CEO Michael Severino outlined a strategic focus on leveraging the company’s existing platform and rare-disease capabilities. Sarepta Q2 Earnings Call Highlights
• Neutral Sentiment: Investors are weighing a revised 2026 outlook. Sarepta updated and narrowed its 2026 product-revenue guidance, signaling more clarity but also reflecting uncertainty around the pace of its commercial recovery.
• Negative Sentiment: Elevidys sales were weaker and revenue declined year over year. Quarterly revenue fell 34.3% from the prior-year period, and earnings dropped from $2.02 per share to $0.64, underscoring pressure on the company’s lead product.
• Negative Sentiment: Competitive pressure remains a risk. RBC noted that Sarepta is undergoing a strategic transition under its new CEO while facing increasing competition, which could limit Elevidys growth and make the pipeline’s eventual contribution more important. RBC on Sarepta Competitive Pressures

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC boosted its holdings in shares of Sarepta Therapeutics by 454.6% during the 4th quarter. AQR Capital Management LLC now owns 7,796,535 shares of the biotechnology company’s stock worth $167,781,000 after buying an additional 6,390,860 shares during the period. First Trust Advisors LP boosted its stake in Sarepta Therapeutics by 2.7% during the 4th quarter. First Trust Advisors LP now owns 1,992,577 shares of the biotechnology company’s stock valued at $42,880,000 after purchasing an additional 52,796 shares during the period. Geode Capital Management LLC boosted its stake in Sarepta Therapeutics by 10.6% during the 4th quarter. Geode Capital Management LLC now owns 1,904,325 shares of the biotechnology company’s stock valued at $40,990,000 after purchasing an additional 183,201 shares during the period. Federated Hermes Inc. grew its holdings in Sarepta Therapeutics by 0.4% in the 4th quarter. Federated Hermes Inc. now owns 1,313,313 shares of the biotechnology company’s stock valued at $28,262,000 after buying an additional 4,622 shares during the last quarter. Finally, Millennium Management LLC increased its position in Sarepta Therapeutics by 251.9% in the 4th quarter. Millennium Management LLC now owns 1,000,109 shares of the biotechnology company’s stock worth $21,522,000 after buying an additional 715,899 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.